<DOC>
	<DOCNO>NCT00871689</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation donor umbilical cord blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell natural killer cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Giving interleukin-2 ( IL-2 , aldesleukin ) transplant may stimulate natural killer cell kill remain cancer cell . PURPOSE : This phase II trial study side effect give combination chemotherapy together total-body irradiation follow interleukin-2 ( IL-2 , aldesleukin ) , umbilical cord blood transplant see well work treat patient relapsed refractory acute myeloid leukemia .</brief_summary>
	<brief_title>Chemotherapy , Total-Body Irradiation , Donor Natural Killer Cell Infusion , Aldesleukin , UCB Transplant Treating Patients With Relapsed Refractory AML</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine rate neutrophil engraftment grade III-IV acute graft-versus-host disease ( GVHD ) follow T cell deplete ( TCD ) umbilical cord blood ( UCB ) transplantation without post-transplant immunosuppression follow administration interleukin-2 ( IL-2 , aldesleukin ) ( every day ) day +3 +13 expand NK cell vivo . Secondary - To evaluate safety regimen assess monitor rate graft failure , acute GVHD , transplant-related mortality ( TRM ) . - To perform quantitative , phenotypic , functional assessment vivo expand UCB-derived NK cell ( day +72 ) . - To assess clinical disease response ( leukemia clearance complete remission ) survival duration patient . - To evaluate tolerability aldesleukin patient . - To evaluate tolerance IL-2 OUTLINE : - Preparative regimen : Patients receive fludarabine phosphate intravenously ( IV ) 1 hour day -7 -5 cyclophosphamide IV day -7 -6 . Patients undergo total-body irradiation twice daily day -5 -2 . - Transplantation : Patients undergo T-cell deplete umbilical cord blood ( UCB ) transplantation day 0 . - IL-2 ( Aldesleukin ) therapy : Patients receive aldesleukin subcutaneously day +3 6 dos every day ) +60 ( 6 dos every day ) . Patients follow periodically 2 year transplant .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Aged 0 45 year meet one follow criterion : Primary induction failure define complete remission ( CR ) two three induction cycle ( blast limit ) . Relapsed acute myeloid leukemia ( AML ) low disease burden For patient 19 45 year age : must less 10 % marrow blast time enrollment patient receive reinduction measure least 28 day start reinduction therapy . Patients relapse 12 month follow prior hematopoietic cell transplant ( HCT ) reach CR follow one reinduction cycle le 10 % marrow blast eligible . For patient 0 18 year age : must less 50 % marrow blast 3 induction attempt CR3 great . This include CRp define CR without platelet recovery 100,000/mcL . CR1 CR2 high risk feature ( therapy induce , prior myelodysplastic syndrome ( MDS ) myeloproliferative disease ( MPD ) , high risk cytogenetic molecular phenotype ) available alternate ( sibling , URD UCB ) donor . Patients prior central nervous system ( CNS ) involvement eligible provide treated remission . CNS therapy ( chemotherapy radiation ) continue medically indicate protocol . Have acceptable organ function within 14 day enrollment define : Renal : creatinine ≤ 2.0 mg/dL ( adult patient ) calculate creatinine clearance &gt; 40 ml/min ( pediatric patient ) Hepatic : bilirubin , AST/ALT , ALP ≤ 5 x upper limit normal Pulmonary function : DLCOcorr &gt; 50 % normal , ( oxygen saturation [ &gt; 92 % ] use child PFT 's obtain ) Cardiac : leave ventricular ejection fraction ≥ 45 % Karnofsky score ( adult ) &gt; 70 % Lansky score &gt; 50 % ( pediatrics ) Women childbearing potential must agree use adequate contraception ( diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , subcutaneous implant , abstinence , etc . ) duration treatment . All patient question prior exposure antibody therapy ( include OKT3 , rituximab , trastuzumab , gemtuzumab ) without affect eligibility . Patients prior exposure blood sample collect human antimouse antibody ( HAMA ) . For patient prior antibody therapy exposure , action take . Not receive prednisone immunosuppressive medication Voluntary write consent Active infection time enrollment document fungal infection within 3 month Evidence HIV infection know HIV positive serology Pregnant breast feeding . The agent use study may teratogenic fetus information excretion agent breast milk . All female childbearing potential must blood test urine study within 2 week prior registration rule pregnancy . If ≤ 18 year old , prior myeloablative transplant within last 6 month . If &gt; 18 year old prior myeloablative allotransplant autologous transplant Extensive prior therapy include &gt; 12 month alkylator chemotherapy ( etoposide &gt; 100 mg/m^2 x 5 day , cyclophosphamide &gt; 1 gm/m^2 mitoxantrone &gt; 8 gm/m^2 ) deliver 34 week interval &gt; 6 month alkylator therapy ( ) extensive radiation ( determine Radiation Oncology , e.g . mantle irradiation Hodgkin 's ) and/or prior radiation therapy make patient ineligible total body irradiation ( TBI ) . Criteria Second Course IL2 ( begin day +60 ) : No GraftVersusHost Disease ( GVHD ) , active infection severe medical comorbidity Absolute neutrophil count ( ANC ) &gt; 1000 without growth factor support No grade 4 toxicity ( except fever ) attribute IL2 course # 1</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>childhood acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>childhood acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>childhood acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>